Jefferies Maintains Buy on Kennametal, Lowers Price Target to $35
Jefferies analyst Stephen Volkmann maintains Kennametal (NYSE:KMT) with a Buy and lowers the price target from $45 to $35.
Raymond James Maintains Strong Buy on United Parcel Service, Lowers Price Target to $225
Raymond James analyst Patrick Tyler Brown maintains United Parcel Service (NYSE:UPS) with a Strong Buy and lowers the price target from $250 to $225.
Jefferies Maintains Buy on Timken, Lowers Price Target to $75
Jefferies analyst Stephen Volkmann maintains Timken (NYSE:TKR) with a Buy and lowers the price target from $85 to $75.
Jefferies Maintains Hold on Trane Technologies, Lowers Price Target to $140
Jefferies analyst Stephen Volkmann maintains Trane Technologies (NYSE:TT) with a Hold and lowers the price target from $160 to $140.
SVB Leerink Initiates Coverage On Certara with Outperform Rating, Announces Price Target of $29
SVB Leerink analyst Joy Zhang initiates coverage on Certara (NASDAQ:CERT) with a Outperform rating and announces Price Target of $29.
SVB Leerink Initiates Coverage On IQVIA Hldgs with Outperform Rating, Announces Price Target of $256
SVB Leerink analyst Joy Zhang initiates coverage on IQVIA Hldgs (NYSE:IQV) with a Outperform rating and announces Price Target of $256.
Credit Suisse Maintains Neutral on Conagra Brands, Lowers Price Target to $35
Credit Suisse analyst Robert Moskow maintains Conagra Brands (NYSE:CAG) with a Neutral and lowers the price target from $36 to $35.
UBS Maintains Buy on JPMorgan Chase, Lowers Price Target to $126
UBS analyst Erika Najarian maintains JPMorgan Chase (NYSE:JPM) with a Buy and lowers the price target from $134 to $126.
SVB Leerink Initiates Coverage On Omnicell with Market Perform Rating, Announces Price Target of $124
SVB Leerink analyst Joy Zhang initiates coverage on Omnicell (NASDAQ:OMCL) with a Market Perform rating and announces Price Target of $124.
Raymond James Maintains Outperform on Abbott Laboratories, Lowers Price Target to $117
Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $135 to $117.